Literature DB >> 6322678

Alpha-interferon administration in cytomegalovirus retinitis.

S W Chou, J S Dylewski, M W Gaynon, P R Egbert, T C Merigan.   

Abstract

Four patients, including three with the acquired immunodeficiency syndrome (AIDS), were treated with high-dose, buffy coat-derived alpha-interferon for progressive cytomegalovirus retinitis. Two of these patients had decreased viruria during therapy and the other two had increased viruria. There was evidence of progression of disease despite therapy in all patients, although the retinitis eventually became quiescent in the patient without AIDS. The severe immunosuppression encountered in AIDS patients complicates the management of cytomegalovirus and other opportunistic infections.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6322678      PMCID: PMC185427          DOI: 10.1128/AAC.25.1.25

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  11 in total

1.  Acyclovir in immunocompromised patients with cytomegalovirus disease. A controlled trial at one institution.

Authors:  H H Balfour; B Bean; C D Mitchell; G W Sachs; J R Boen; C K Edelman
Journal:  Am J Med       Date:  1982-07-20       Impact factor: 4.965

2.  Physical properties of human interferon prepared in vitro and in vivo.

Authors:  T C Merigan; D F Gregory; J K Petralli
Journal:  Virology       Date:  1966-08       Impact factor: 3.616

3.  Cytomegalovirus retinitis in immunosuppressed hosts. II. Ocular manifestations.

Authors:  P R Egbert; R B Pollard; J G Gallagher; T C Merigan
Journal:  Ann Intern Med       Date:  1980-11       Impact factor: 25.391

4.  A trial of vidarabine for cytomegalovirus infection in renal transplant patients.

Authors:  S C Marker; R J Howard; K E Groth; A R Mastri; R L Simmons; H H Balfour
Journal:  Arch Intern Med       Date:  1980-11

5.  Treatment of cytomegalovirus pneumonia with high-dose acyclovir.

Authors:  J C Wade; M Hintz; R McGuffin; S C Springmeyer; J D Connor; J D Meyers
Journal:  Am J Med       Date:  1982-07-20       Impact factor: 4.965

6.  Ocular disorders associated with a new severe acquired cellular immunodeficiency syndrome.

Authors:  G N Holland; M S Gottlieb; R D Yee; H M Schanker; T H Pettit
Journal:  Am J Ophthalmol       Date:  1982-04       Impact factor: 5.258

7.  Treatment of cytomegalovirus pneumonia after marrow transplant with combined vidarabine and human leukocyte interferon.

Authors:  J D Meyers; R W McGuffin; Y J Bryson; K Cantell; E D Thomas
Journal:  J Infect Dis       Date:  1982-07       Impact factor: 5.226

8.  Toxicity and efficacy of human leukocyte interferon for treatment of cytomegalovirus pneumonia after marrow transplantation.

Authors:  J D Meyers; R W McGuffin; P E Neiman; J W Singer; E D Thomas
Journal:  J Infect Dis       Date:  1980-05       Impact factor: 5.226

9.  Effect of leukocyte interferon on urinary excretion of cytomegalovirus by infants.

Authors:  A M Arvin; A S Yeager; T C Merigan
Journal:  J Infect Dis       Date:  1976-06       Impact factor: 5.226

10.  Virus-specific IgG and IgM antibodies in normal and immunocompromised subjects infected with cytomegalovirus.

Authors:  L Rasmussen; D Kelsall; R Nelson; W Carney; M Hirsch; D Winston; J Preiksaitis; T C Merigan
Journal:  J Infect Dis       Date:  1982-02       Impact factor: 5.226

View more
  2 in total

1.  Effect of 2'-nor-cyclic GMP against guinea pig cytomegalovirus infection.

Authors:  Z H Yang; H L Lucia; R L Tolman; R J Colonno; G D Hsiung
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191

2.  Therapeutic use of ganciclovir for invasive cytomegalovirus infection in cadaveric renal allograft recipients.

Authors:  M L Jordan; R L Hrebinko; J S Dummer; D P Hickey; R Shapiro; C A Vivas; R L Simmons; T E Starzl; T R Hakala
Journal:  J Urol       Date:  1992-11       Impact factor: 7.450

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.